Mustang Bio, Inc.Announces Registered Direct Offering and Private Placement to Advance Cell Therapies for Cancer Treatment
Worcester, Mass.June 20, 2024 Mustang Bio, Inc.(Nasdaq: MBIO) has recently made significant strides in the field of biopharmaceuticals with the announcement of a definitive agreement for the issuance and sale of 6,130,000 shares of its common stock in a registered direct offering priced at $0.41 per share.This offering, conducted under Nasdaq rules, represents a crucial step in Mustang’s mission to translate cutting-edge medical breakthroughs in cell therapies into potential cures for challenging-to-treat cancers.
In addition to the registered direct offering, Mustang has also engaged in a concurrent private placement, where the company will issue and sell unregistered warrants to purchase up to 6,130,000 shares of its common stock.This strategic move is aimed at bolstering Mustang’s research and development efforts in the field of oncology, furthering their commitment to revolutionizing cancer treatment through innovative cell therapies.
The offering, slated to close on or about June 21, 2024, is subject to customary closing conditions, underscoring Mustang’s dedication to regulatory compliance and transparency.With this infusion of capital, Mustang is positioned to advance its pipeline of novel therapeutic solutions, paving the way for potential breakthroughs in cancer care.
Mustang Bio, Inc.continues to be at the forefront of advancing cell-based therapies for the treatment of cancer, and this latest offering is a testament to their unwavering commitment to medical innovation.Stay tuned for further developments as Mustang pushes the boundaries of possibility in the fight against cancer.
Comments